BUSINESS WIRE
PLANO, Texas--(BUSINESS WIRE)--MacuCLEAR, Inc. (“MacuCLEAR”) announced today it has entered into a
collaborative business relationship with Mystic Pharmaceuticals Inc. for
its upcoming Phase I/II Human Clinical Trials. MacuCLEAR is developing
MC 1101, for the treatment and prevention of the progression of Age
Related Macular Degeneration (AMD). Mystic Pharmaceuticals, Inc.
(“Mystic”) has developed a novel unit dose drug delivery platform
capable of preservative free, precision delivery of ophthalmic drugs.
“We believe Mystic’s novel VersiDoser™ delivery system will help
overcome many of the challenges of topical delivery of ophthalmic drugs
to the eye,” said Philip G. Ralston, Jr., President and CEO of
MacuCLEAR. “Standard eyedroppers typically deliver too large a drop that
'floods' the eye. Conventional eyedroppers waste product and are
difficult for elderly patients to use reliably on a daily basis.
Mystic’s individually packaged drops can be precisely sized and
accurately delivered with a unique dispenser that is easy to use.”
Ralston added, “The Mystic dispenser counts the drops delivered, which
will be helpful in tracking compliance and accounting for the usage of a
reimbursed product.”
Mystic Pharmaceuticals’ President and CEO, Timothy Sullivan, stated, “We
are pleased to work with MacuCLEAR in their clinical program. Their drug
has shown promise throughout its preclinical program and has received
fast track status from the FDA. AMD is a growing healthcare problem for
our aging population. Our delivery systems are uniquely designed to
safely and effectively deliver drugs to low vision and elderly people.
The combination of these two technologies offers great potential for
addressing a terrible disease resulting in loss of vision.”
Ralston and Sullivan jointly announced the collaboration at the
OneMedPlace Emerging Healthcare Technologies Finance Forum at the Drake
Hotel in San Francisco today.
About MacuCLEAR: MacuCLEAR, Inc. is a specialty
pharmaceutical development company, based in Plano, Texas. Its lead
compound, MC1101 is a novel, topically delivered solution for the
treatment and prevention of the progression of the Dry or early stage of
age related macular degeneration, which afflicts 90% of all who have
AMD. This technology was invented at Texas A&M University by George C.Y.
Chiou, PhD, who led the development of Timolol, a pioneering treatment
for glaucoma.
For more information please visit the MacuCLEAR website: www.macuclear.com
About Mystic Pharmaceuticals, Inc.
Mystic Pharmaceuticals™ is an integrated specialty pharmaceutical
company based in Austin, Texas. Mystic develops precision unit dose
ophthalmic and intranasal drug delivery platforms for pharmaceuticals,
biopharmaceuticals and vaccines. Mystic combines its novel drug delivery
systems with a pipeline of pharmaceuticals and biologics under
development by Mystic or its partners, to meet the expanding global
market demand for medications which are lower cost, safer and easier to
use for consumers.
For more information please visit the Mystic website: www.mysticpharmaceuticals.com